As Of	Filer	Filing¹	For·On·As	Docs:Size	Issuer		Filing Agent

 6/21/19  Huang James                       4          Director²   1:5K   CASI Pharmaceuticals, Inc. (DE)   Toppan Merrill/FA        
 6/21/19  Ren Ken Keyong                    4          Director²   1:5K   CASI Pharmaceuticals, Inc. (DE)   Toppan Merrill/FA        
 6/21/19  Salisbury Franklin Cary jr        4          Director²   1:5K   CASI Pharmaceuticals, Inc. (DE)   Toppan Merrill/FA        
 6/21/19  Shrotriya Rajesh C MD             4          Director²   1:5K   CASI Pharmaceuticals, Inc. (DE)   Toppan Merrill/FA        
 6/21/19  Wu Yue Alexander                  4          Director²   1:5K   CASI Pharmaceuticals, Inc. (DE)   Toppan Merrill/FA        
 6/21/19  He Wei-Wu                         4          D,O,%Owner² 1:5K   CASI Pharmaceuticals, Inc. (DE)   Toppan Merrill/FA        
 6/21/19  Zhou Quan                         4          Dir.,%Own.² 1:5K   CASI Pharmaceuticals, Inc. (DE)   Toppan Merrill/FA        
 6/21/19  CASI Pharmaceuticals, Inc. (DE)   8-K:5,9     6/20/19    1:31K                                    Toppan Merrill/FA        
 4/30/19  CASI Pharmaceuticals, Inc. (DE)   DEF 14A     6/20/19    1:699K                                   Toppan Merrill/FA        

____________
¹	Filing/Form Types:  -K
	4	Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 { The Filer is an Insider² of the Issuer }.
	8-K	Current Report — Form 8-K { Item 1: Business & Operations;  2: Financial Info;  3: Securities & Trading;  4: Accountants & Accounting;  5: Governance & Management;  6: Asset-Backed Securities;  7: Disclosures;  8: Events;  9: Financials }.
	DEF 14A	Definitive Proxy Statement — Schedule 14A.
²	Insider:  The Filer is a Director, Officer, 10% Owner and/or Other “insider” of the Issuer.